Calibrating RWE studies in oncology against randomized trials
Active Definitive Contract Awarded Last action
- Contract number
- 75F40122C00181
- Awardee
-
Brigham & Womens Hospital Inc. UEI QN6MS4VN7BD1 Part of Partners Healthcare System Incorporated
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $3,700,000
Award facts
- Contract value 79% obligated
- $4,691,150.00 Current and potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $991,150 | |
| Other Administrative Action | $0 | |
| Original award | $2,708,850 |
About this award
The Food and Drug Administration (FDA) awarded a $4,691,150.00 firm fixed price contract to Brigham & Women's Hospital Inc. to conduct research on calibrating real-world evidence (RWE) studies in oncology against randomized clinical trials. The contract has a completion date of January 29, 2027 and does not have a small business set-aside designation. Brigham & Women's Hospital is a subsidiary of the larger Partners Healthcare System Incorporated, which is a major integrated healthcare system in Boston. Partners Healthcare and its subsidiaries have extensive experience conducting biomedical and clinical research across various specialties with support from federal contracts and grants. This contract aligns with the FDA's initiatives to leverage RWE to complement traditional randomized controlled trials for oncology product evaluations.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Dana-Farber Cancer Institute, Inc. | $134,159 |
Quick answers
Who was awarded contract 75F40122C00181?
75F40122C00181 was awarded to Brigham & Womens Hospital Inc. by Food and Drug Administration (Department of Health and Human Services) on September 21, 2022.
How much is contract 75F40122C00181 worth?
The government has obligated $3,700,000 on 75F40122C00181. Its current value, with exercised options, is $4,691,150.
Was contract 75F40122C00181 competed?
The extent of competition for 75F40122C00181 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award